Catalent joins the EuropaBio 25th Anniversary in 2021
EuropaBio today announced that Catalent has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.
Showing Results 131-140 Of 76 For Italy
Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in Limoges, France
Catalent today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.
Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.
Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
Moderna and Catalent today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at Catalent’s facility in Bloomington, Indiana.
Catalent Expands OneBio® Suite for Integrated Development, Manufacturing and Supply Across Biologic Modalities
OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.